Showing results (101-110 of 263) with videos related to
Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancerA van der Gaast, C Hulshof, T C Kok, et al.Seminars in Oncology|April 1, 1992
The European Organization for Research and Treatment of Cancer experience with teniposide: preliminary results of a randomized study in non-small cell lung cancerG Giaccone, T A Splinter, A Kirkpatrick, et al.Cancer Chemotherapy and Pharmacology|July 27, 2000
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utilityF M Sirotnak, L Sepp-Lorenzino, N E Kohl, et al.Seminars in Oncology|October 1, 1996
Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/cisplatin in patients with non-small cell lung cancer. EORTC Lung Cancer Cooperative GroupP E Postmus, G Giaccone, C Debruyne, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1994
Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancerA van der Gaast, M Bontenbal, A S Planting, et al.European Journal of Cancer (Oxford, England : 1990)|October 1, 1995
Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancerA van der Gaast, T C Kok, G S Kho, et al.Seminars in Urology|February 1, 1992
Therapeutic alternatives for hormone-refractory prostatic cancerH I Scher, T Curley, S Yeh, et al.Journal of Chromatography|April 8, 1988
Quantitation of polyamines in cultured cells and tissue homogenates by reversed-phase high-performance liquid chromatography of their benzoyl derivativesC F Verkoelen, J C Romijn, F H Schroeder, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinaseF M Sirotnak, M F Zakowski, V A Miller, et al.Urology|August 1, 1994
Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterinP K Schultz, W K Kelly, C Begg, et al.Pageof 27